Rafferty Asset Management LLC Cuts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Rafferty Asset Management LLC trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 36.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 234,836 shares of the biotechnology company's stock after selling 136,198 shares during the quarter. Rafferty Asset Management LLC owned approximately 0.11% of BioCryst Pharmaceuticals worth $1,766,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BCRX. ProShare Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 32.6% during the 4th quarter. ProShare Advisors LLC now owns 68,004 shares of the biotechnology company's stock worth $511,000 after buying an additional 16,732 shares during the last quarter. Quantinno Capital Management LP raised its position in shares of BioCryst Pharmaceuticals by 38.2% during the 4th quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 4,097 shares in the last quarter. Man Group plc raised its position in shares of BioCryst Pharmaceuticals by 46.3% during the 4th quarter. Man Group plc now owns 89,954 shares of the biotechnology company's stock worth $676,000 after acquiring an additional 28,481 shares in the last quarter. Lazard Asset Management LLC lifted its stake in BioCryst Pharmaceuticals by 68.1% during the fourth quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company's stock worth $1,214,000 after purchasing an additional 65,420 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $731,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX traded up $0.20 on Monday, reaching $10.59. The company's stock had a trading volume of 3,608,168 shares, compared to its average volume of 3,026,377. BioCryst Pharmaceuticals, Inc. has a 52-week low of $5.92 and a 52-week high of $11.11. The stock has a market capitalization of $2.22 billion, a P/E ratio of -17.36 and a beta of 1.08. The stock's 50-day moving average is $8.38 and its two-hundred day moving average is $8.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. During the same period in the previous year, the company posted $0.28 earnings per share. The firm's revenue was up 40.8% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on BCRX. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price objective on the stock. Finally, Wedbush initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.